ACTU Actuate Therapeutics, Inc.
Financings ·
Actuate Therapeutics priced 30,985,900 shares and warrants for 15,492,950 more shares at $0.71 per set, for about $11.0 million before costs. The stock last sold at $0.40, and the company reported $4.4 million of cash at June 30, 2026.
Actuate Therapeutics priced 2,142,858 shares at $7.00 for $15,000,006 in gross proceeds, below the $8.24 last sale price. Lucid Capital Markets is the sole underwriter, and the prospectus says the company's current liabilities exceeded its assets at June 30, 2025.
The deal pairs each share with a $7.00 warrant and is expected to bring in approximately $4.7 million in gross proceeds. Bios 2024 Co-Invest, LP, a current stockholder, is among the purchasers, and the filing says Bios would be deemed to own about 49.9% of the company.
Actuate Therapeutics filed a corporate overview dated May 31, 2025 that repeats its going-concern warning and says it needs capital to fund operations beyond the second quarter of fiscal 2025. The deck's survival figures are draft, unaudited data, and its progression-free survival result is not statistically significant.
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). Its lead asset is elraglusib, an ATP-competitive small molecule that the company says blocks GSK-3β, a master regulator of signaling pathways that lead to tumor cell survival, growth, migration and invasion. The company has exclusively licensed elraglusib from a collaboration between the University of Illinois-Chicago and Northwestern University. Its most advanced indication is first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). A randomized, controlled Phase 2 trial in that setting, Actuate-1801 Part 3B, enrolled 286 patients, and data presented at ASCO GI in January 2026 showed that the trial met its primary endpoint of median overall survival. The company is also developing elraglusib in pediatric cancers, where it identified Ewing sarcoma and neuroblastoma as new indications. It has selected an oral tablet formulation for further development and plans a Phase 1 study, subject to future funding. Elraglusib holds orphan drug designations for pancreatic and other cancer types and fast track designation for pancreatic cancer.
| Product or program | What it is | Stage |
|---|---|---|
| Elraglusib Injection (mPDAC) | GSK-3β inhibitor given with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer | Phase 2 trial met primary endpoint |
| Elraglusib Injection (pediatric) | Intravenous GSK-3β inhibitor for recurrent or refractory pediatric solid cancers | Phase 1/2 (Actuate-1902) |
| Elraglusib Oral Tablet | Oral dosage form for advanced, refractory cancers | Phase 1 planned, subject to future funding |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $10.3 million | $18.7 million |
| Net income (loss) | -$22.2 million | -$27.3 million |
| Cash from operations | -$19.2 million | -$21.8 million |
| Cash and equivalents | $13.2 million | $8.6 million |
Our latest story on this, dated Jun 2, 2025: "Actuate Therapeutics presentation repeats going-concern doubt and need for capital". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 28, 2026: "Actuate Therapeutics prices $11.0 million offering of shares and warrants". The story links the filing or release it is based on. Read the story.
Actuate Therapeutics, Inc. trades under the ticker ACTU on NASDAQ.
Actuate Therapeutics, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Actuate Therapeutics, Inc. is 1652935. Its filings are on SEC EDGAR.
24,014,202 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Actuate Therapeutics, Inc. under United States.
Our directory classifies Actuate Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Actuate Therapeutics, Inc. is US0050831009.
aibio.space lists Actuate Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing therapies for high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). Its lead asset is elraglusib, an ATP-competitive small molecule that the company says blocks GSK-3β, a master regulator of signaling pathways that lead to tumor cell survival, growth, migration and invasion.
Elraglusib Injection (mPDAC): GSK-3β inhibitor given with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer Stage: Phase 2 trial met primary endpoint.
Elraglusib Injection (pediatric): Intravenous GSK-3β inhibitor for recurrent or refractory pediatric solid cancers Stage: Phase 1/2 (Actuate-1902).
Actuate Therapeutics, Inc. reported a net loss of $22.2 million for the fiscal year ended Dec 31, 2025, and used $19.2 million of cash in operations, per its annual report to the SEC.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Filed a registration statement for a share offering. SEC Form S-1. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio